{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:38:33Z","timestamp":1792604313648,"version":"4.5.0"},"publisher-location":"Cham","reference-count":53,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783032294364","type":"print"},{"value":"9783032294371","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-3-032-29437-1_14","type":"book-chapter","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:15Z","timestamp":1792601475000},"page":"235-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Investigation of Antibody\u2013Drug Conjugates by Mass Spectrometry"],"prefix":"10.1007","author":[{"given":"Aneeta","family":"Arshad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rylie","family":"Flack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora Barbosa","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costel C.","family":"Darie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuri","family":"Jayathirtha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2027,1,23]]},"reference":[{"issue":"9","key":"14_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4155\/bio.13.38","volume":"5","author":"B Gorovits","year":"2013","unstructured":"Gorovits B et al (2013) Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 5(9):997\u20131006","journal-title":"Bioanalysis"},{"issue":"4","key":"14_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis N, Banerji U (2016) Antibody-drug conjugates\u2014an emerging class of cancer treatment. Br J Cancer 114(4):362\u2013367","journal-title":"Br J Cancer"},{"issue":"11","key":"14_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1359-6446(03)02714-4","volume":"8","author":"MJ Glennie","year":"2003","unstructured":"Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8(11):503\u2013510","journal-title":"Drug Discov Today"},{"key":"14_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","volume":"18","author":"L Shefet-Carasso","year":"2015","unstructured":"Shefet-Carasso L, Benhar I (2015) Antibody-targeted drugs and drug resistance\u2014Challenges and solutions. Drug Resist Updates 18:36\u201346","journal-title":"Drug Resist Updates"},{"issue":"9","key":"14_CR5","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1517\/14712598.2012.693473","volume":"12","author":"JR Adair","year":"2012","unstructured":"Adair JR et al (2012) Antibody\u2013drug conjugates \u2013 a perfect synergy. Expert Opin Biol Ther 12(9):1191\u20131206","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"14_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1021\/ar700108g","volume":"41","author":"RVJ Chari","year":"2008","unstructured":"Chari RVJ (2008) Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs. Acc Chem Res 41(1):98\u2013107","journal-title":"Acc Chem Res"},{"issue":"3","key":"14_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K et al (2024) Exploring the next generation of antibody\u2013drug conjugates. Nat Rev Clin Oncol 21(3):203\u2013223","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"14_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cbdd.12085","volume":"81","author":"JA Flygare","year":"2013","unstructured":"Flygare JA, Pillow TH, Aristoff P (2013) Antibody\u2013drug conjugates for the treatment of cancer. Chem Biol Drug Des 81(1):113\u2013121","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"14_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/bc900315y","volume":"21","author":"HK Erickson","year":"2010","unstructured":"Erickson HK et al (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody\u2212maytansinoid conjugates. Bioconjug Chem 21(1):84\u201392","journal-title":"Bioconjug Chem"},{"issue":"4","key":"14_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<697::AID-CNCR12>3.0.CO;2-T","volume":"82","author":"J Kigawa","year":"1998","unstructured":"Kigawa J et al (1998) Glutathione concentration may be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 82(4):697\u2013702","journal-title":"Cancer"},{"issue":"9","key":"14_CR11","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1110\/ps.051478705","volume":"14","author":"L Wang","year":"2005","unstructured":"Wang L et al (2005) Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 14(9):2436\u20132446","journal-title":"Protein Sci"},{"issue":"20","key":"14_CR12","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","volume":"10","author":"KJ Hamblett","year":"2004","unstructured":"Hamblett KJ et al (2004) Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10(20):7063\u20137070","journal-title":"Clin Cancer Res"},{"key":"14_CR13","doi-asserted-by":"crossref","unstructured":"Yang J et al (2024) Detailed structural elucidation of an antibody\u2013drug conjugate, AZD8205, biotransformation species using LC-MRM with CID and EAD fragmentation.","DOI":"10.26434\/chemrxiv-2024-6qc19"},{"issue":"4","key":"14_CR14","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1021\/acs.bioconjchem.7b00785","volume":"29","author":"D Su","year":"2018","unstructured":"Su D et al (2018) Modulating antibody\u2013drug conjugate payload metabolism by conjugation site and linker modification. Bioconjug Chem 29(4):1155\u20131167","journal-title":"Bioconjug Chem"},{"issue":"2","key":"14_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/ph11020032","volume":"11","author":"N Dan","year":"2018","unstructured":"Dan N et al (2018) Antibody\u2013drug conjugates for cancer therapy: chemistry to clinical implications. Pharmaceuticals (Basel) 11(2):32. p","journal-title":"Pharmaceuticals (Basel)"},{"key":"14_CR16","doi-asserted-by":"crossref","unstructured":"Parslow CA et al (2016) Antibody\u2013drug conjugates for cancer therapy. Biomedicines 4(3).","DOI":"10.3390\/biomedicines4030014"},{"issue":"8","key":"14_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C et al (2023) Antibody\u2013drug conjugates come of age in oncology. Nat Rev Drug Discovery 22(8):641\u2013661","journal-title":"Nat Rev Drug Discovery"},{"issue":"22","key":"14_CR18","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","volume":"124","author":"SM Ansell","year":"2014","unstructured":"Ansell SM (2014) Brentuximab vedotin. Blood 124(22):3197","journal-title":"Blood"},{"issue":"13","key":"14_CR19","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1182\/blood.V96.13.4307","volume":"96","author":"SS Mir","year":"2000","unstructured":"Mir SS, Richter BWM, Duckett CS (2000) Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96(13):4307","journal-title":"Blood"},{"issue":"13","key":"14_CR20","first-page":"3736","volume":"62","author":"AF Wahl","year":"2002","unstructured":"Wahl AF et al (2002) The anti-CD30 monoclonal antibody SGN-30 promotesgrowth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin\u2019s disease. Cancer Res 62(13):3736","journal-title":"Cancer Res"},{"issue":"3","key":"14_CR21","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","volume":"16","author":"NM Okeley","year":"2010","unstructured":"Okeley NM et al (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody\u2013drug conjugate. Clin Cancer Res 16(3):888","journal-title":"Clin Cancer Res"},{"key":"14_CR22","first-page":"37","volume":"6","author":"M Sawaki","year":"2014","unstructured":"Sawaki M (2014) Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Breast cancer (Dove Medical Press) 6:37\u201341","journal-title":"Breast cancer (Dove Medical Press)"},{"issue":"1","key":"14_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA (2007) Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med 357(1):39\u201351.","journal-title":"N Engl J Med"},{"issue":"5","key":"14_CR24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clbc.2011.03.018","volume":"11","author":"HA Burris","year":"2011","unstructured":"Burris HA et al (2011) Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer. Clin Breast Cancer 11(5):275\u2013282","journal-title":"Clin Breast Cancer"},{"key":"14_CR25","first-page":"329","volume":"7","author":"S Sadeghi","year":"2014","unstructured":"Sadeghi S, Olevsky O, Hurvitz SA (2014) Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmgenomics Pers Med 7:329\u2013338","journal-title":"Pharmgenomics Pers Med"},{"issue":"11","key":"14_CR26","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1177\/1060028014545354","volume":"48","author":"PA Corrigan","year":"2014","unstructured":"Corrigan PA et al (2014) Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. Ann Pharmacother 48(11):1484\u20131493","journal-title":"Ann Pharmacother"},{"key":"14_CR27","doi-asserted-by":"crossref","unstructured":"Barok, M, H Joensuu H, and J Isola J (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res, 2014. 16(2):209","DOI":"10.1186\/bcr3621"},{"issue":"24","key":"14_CR28","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1182\/blood-2013-03-490482","volume":"121","author":"JM Rowe","year":"2013","unstructured":"Rowe JM, L\u00f6wenberg B (2013) Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 121(24):4838","journal-title":"Blood"},{"issue":"6","key":"14_CR29","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","volume":"11","author":"J Baron","year":"2018","unstructured":"Baron J, Wang ES (2018) Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol 11(6):549\u2013559","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"14_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1517\/14712598.2011.543895","volume":"11","author":"M Breccia","year":"2011","unstructured":"Breccia M, Lo-Coco F (2011) Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther 11(2):225\u2013234","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"14_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3324\/haematol.2016.145763","volume":"101","author":"T de Witte","year":"2016","unstructured":"de Witte T, Amadori S (2016) The optimal dosing of gemtuzumab ozagamicin: where to go from here? Haematologica 101(6):653\u2013654","journal-title":"Haematologica"},{"issue":"9","key":"14_CR32","doi-asserted-by":"publisher","first-page":"e24265","DOI":"10.1371\/journal.pone.0024265","volume":"6","author":"E Jager","year":"2011","unstructured":"Jager E et al (2011) Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS One 6(9):e24265\u2013e24265","journal-title":"PLoS One"},{"issue":"5","key":"14_CR33","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.drudis.2016.04.004","volume":"21","author":"RYC Huang","year":"2016","unstructured":"Huang RYC, Chen G (2016) Characterization of antibody\u2013drug conjugates by mass spectrometry: advances and future trends. Drug Discovery Today 21(5):850\u2013855","journal-title":"Drug Discovery Today"},{"issue":"2","key":"14_CR34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","volume":"3","author":"A Wakankar","year":"2011","unstructured":"Wakankar A et al (2011) Analytical methods for physicochemical characterization of antibody drug conjugates. Mabs 3(2):161\u2013172","journal-title":"Mabs"},{"issue":"1","key":"14_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4161\/mabs.26773","volume":"6","author":"E Wagner-Rousset","year":"2014","unstructured":"Wagner-Rousset E et al (2014) Antibody\u2013drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion. Mabs 6(1):173\u2013184","journal-title":"Mabs"},{"issue":"1","key":"14_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ab.2011.01.004","volume":"412","author":"K Xu","year":"2011","unstructured":"Xu K et al (2011) Characterization of intact antibody\u2013drug conjugates from plasma\/serum in vivo by affinity capture capillary liquid chromatography\u2013mass spectrometry. Anal Biochem 412(1):56\u201366","journal-title":"Anal Biochem"},{"issue":"1","key":"14_CR37","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drudis.2010.11.003","volume":"16","author":"G Chen","year":"2011","unstructured":"Chen G et al (2011) Characterization of protein therapeutics by mass spectrometry: recent developments and future directions. Drug Discovery Today 16(1):58\u201364","journal-title":"Drug Discovery Today"},{"issue":"17","key":"14_CR38","doi-asserted-by":"publisher","first-page":"6233","DOI":"10.1073\/pnas.83.17.6233","volume":"83","author":"DF Hunt","year":"1986","unstructured":"Hunt DF et al (1986) Protein sequencing by tandem mass spectrometry. Proc Natl Acad Sci 83(17):6233","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"14_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/ja011335z","volume":"124","author":"Y Ge","year":"2002","unstructured":"Ge Y et al (2002) Top down characterization of larger proteins (45 kDa) by electron capture dissociation mass spectrometry. J Am Chem Soc 124(4):672\u2013678","journal-title":"J Am Chem Soc"},{"issue":"26","key":"14_CR40","doi-asserted-by":"publisher","first-page":"9528","DOI":"10.1073\/pnas.0402700101","volume":"101","author":"JEP Syka","year":"2004","unstructured":"Syka JEP et al (2004) Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci U S A 101(26):9528","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"14_CR41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1110\/ps.041062905","volume":"14","author":"JJ Cournoyer","year":"2005","unstructured":"Cournoyer JJ et al (2005) Deamidation: differentiation of aspartyl from isoaspartyl products in peptides by electron capture dissociation. Protein Sci 14(2):452\u2013463","journal-title":"Protein Sci"},{"issue":"1","key":"14_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jasms.2005.08.019","volume":"17","author":"PB O\u2019Connor","year":"2006","unstructured":"O\u2019Connor PB et al (2006) Differentiation of aspartic and isoaspartic acids using electron transfer dissociation. J Am Soc Mass Spectrom 17(1):15\u201319","journal-title":"J Am Soc Mass Spectrom"},{"issue":"5","key":"14_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/mas.20142","volume":"26","author":"J Hardouin","year":"2007","unstructured":"Hardouin J (2007) Protein sequence information by matrix-assisted laser desorption\/ionization in-source decay mass spectrometry. Mass Spectrom Rev 26(5):672\u2013682","journal-title":"Mass Spectrom Rev"},{"issue":"4","key":"14_CR44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1044-0305(01)00218-5","volume":"12","author":"M Takayama","year":"2001","unstructured":"Takayama M (2001) In-source decay characteristics of peptides in matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry. J Am Soc Mass Spectrom 12(4):420\u2013427","journal-title":"J Am Soc Mass Spectrom"},{"issue":"14","key":"14_CR45","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1021\/ac970035q","volume":"69","author":"MM Siegel","year":"1997","unstructured":"Siegel MM et al (1997) Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption\/ionization mass spectrometry and electrospray ionization mass spectrometry. Anal Chem 69(14):2716\u20132726.","journal-title":"Anal Chem"},{"issue":"21","key":"14_CR46","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","volume":"10","author":"FM Veronese","year":"2005","unstructured":"Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10(21):1451\u20131458","journal-title":"Drug Discovery Today"},{"issue":"8","key":"14_CR47","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1007\/s11095-005-5267-7","volume":"22","author":"L Wang","year":"2005","unstructured":"Wang L et al (2005) Structural Characterization of a Recombinant Monoclonal Antibody by Electrospray Time-of-Flight Mass Spectrometry. Pharm Res 22(8):1338\u20131349","journal-title":"Pharm Res"},{"issue":"2","key":"14_CR48","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1021\/jm900899g","volume":"53","author":"S Quiles","year":"2010","unstructured":"Quiles S et al (2010) Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapy. J Med Chem 53(2):586\u2013594","journal-title":"J Med Chem"},{"key":"14_CR49","doi-asserted-by":"publisher","first-page":"123844","DOI":"10.1016\/j.jchromb.2023.123844","volume":"1228","author":"F Yin","year":"2023","unstructured":"Yin F et al (2023) Development and validation of a hybrid immunoaffinity LC\u2013MS\/MS assay for quantitation of total antibody (TAb) from an antibody drug conjugate (ADC) PYX-201 in human plasma. J Chromatogr B 1228:123844","journal-title":"J Chromatogr B"},{"issue":"15","key":"14_CR50","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.1021\/acs.analchem.0c05376","volume":"93","author":"Y Huang","year":"2021","unstructured":"Huang Y et al (2021) Characterization of antibody\u2013drug conjugate pharmacokinetics and in vivo biotransformation using quantitative intact LC-HRMS and surrogate analyte LC-MRM. Anal Chem 93(15):6135\u20136144","journal-title":"Anal Chem"},{"issue":"6","key":"14_CR51","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1021\/acs.analchem.3c04526","volume":"96","author":"B Wei","year":"2024","unstructured":"Wei B et al (2024) Internal Fragments Enhance Middle-Down Mass Spectrometry Structural Characterization of Monoclonal Antibodies and Antibody-Drug Conjugates. Anal Chem 96(6):2491\u20132499","journal-title":"Anal Chem"},{"issue":"42","key":"14_CR52","doi-asserted-by":"publisher","first-page":"16475","DOI":"10.1021\/acs.analchem.4c03383","volume":"96","author":"J Yuan","year":"2024","unstructured":"Yuan J et al (2024) Digestion-free middle-down mass spectrometry method for absolute quantification of conjugated payload from antibody-drug conjugates. Anal Chem 96(42):16475\u201316480","journal-title":"Anal Chem"},{"issue":"29","key":"14_CR53","doi-asserted-by":"publisher","first-page":"10013","DOI":"10.1021\/acs.analchem.1c00150","volume":"93","author":"EJ Larson","year":"2021","unstructured":"Larson EJ et al (2021) High-throughput multi-attribute analysis of antibody-drug conjugates enabled by trapped ion mobility spectrometry and top-down mass spectrometry. Anal Chem 93(29):10013\u201310021","journal-title":"Anal Chem"}],"container-title":["Advances in Experimental Medicine and Biology","Advancements of Mass Spectrometry in Biomedical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-032-29437-1_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:17Z","timestamp":1792601477000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/chapter\/10.1007\/978-3-032-29437-1_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9783032294364","9783032294371"],"references-count":53,"URL":"https:\/\/doi.org\/10.1007\/978-3-032-29437-1_14","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"23 January 2027","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}